Non-coding RNAs in Alzheimer’s disease: perspectives from omics studies

Author:

Wang Erming12,Lemos Duarte Mariana345ORCID,Rothman Lauren E345,Cai Dongming345,Zhang Bin126ORCID

Affiliation:

1. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai , New York, NY 10029, USA

2. Mount Sinai Center for Transformative Disease Modeling, Icahn School of Medicine at Mount Sinai , New York, NY 10029, USA

3. Department of Neurology , Alzheimer’s Disease Research Center and Loeb Center for Alzheimer’s Disease, , New York, NY 10029, USA

4. Icahn School of Medicine at Mount Sinai , Alzheimer’s Disease Research Center and Loeb Center for Alzheimer’s Disease, , New York, NY 10029, USA

5. Research & Development, James J. Peters VA Medical Center , Bronx, NY 10468, USA

6. Icahn Institute of Genomics, Icahn School of Medicine at Mount Sinai , New York, NY 10029, USA

Abstract

Abstract Neurodegenerative diseases such as Alzheimer’s disease (AD) are characterized by the progressive loss of neurons in the brain and the spinal cord. The pathophysiology of AD is multifactorial with heterogeneous molecular manifestations. The lack of efficacious therapies for AD reinforces the importance of exploring in depth multifaceted disease mechanisms. Recent progresses on AD have generated a large amount of RNA-sequencing data at both bulk and single cell levels and revealed thousands of genes with expression changes in AD. However, the upstream regulators of such gene expression changes are largely unknown. Non-coding RNAs (ncRNAs) represent the majority of the human transcriptome, and regulatory ncRNAs have been found to play an important role in regulating gene expression. A single miRNA usually targets a number of mRNAs and thus such ncRNAs are particular important for understanding disease mechanisms and developing novel therapeutics. This review aims to summarize the recent findings on the roles of ncRNAs in AD from ncRNA-omics studies with a focus on ncRNA signatures, interactions between ncRNAs and mRNAs, and ncRNA-regulated pathways in AD. We also review the potential of specific ncRNAs to serve as biomarkers and therapeutic targets for AD. In the end, we point out future directions for studying ncRNAs in AD.

Funder

National Institutes of Health

Department of Veteran Affairs BLRD

Publisher

Oxford University Press (OUP)

Subject

Genetics (clinical),Genetics,Molecular Biology,General Medicine

Reference49 articles.

1. Activities of daily living and associated costs in the most widespread neurodegenerative diseases: a systematic review;Maresova;Clin. Interv. Aging,2020

2. The amyloid-beta pathway in Alzheimer's disease;Hampel;Mol. Psychiatry,2021

3. Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease;Dhapola;Inflammopharmacology,2021

4. Oxidative stress and beta amyloid in Alzheimer's disease. Which comes first: the chicken or the egg?;Tamagno;Antioxidants (Basel),2021

5. Microglia regulation of synaptic plasticity and learning and memory;Cornell;Neural Regen. Res.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3